Aethlon Medical (AEMD) Stock Price, News & Analysis

Company Overview

Aethlon Medical, Inc. (NASDAQ: AEMD) is a clinical‐stage biotechnology company focused on developing novel immunotherapeutic medical devices to address life‐threatening diseases. The company’s lead product candidate, the Hemopurifier®, is an extracorporeal affinity device designed to remove circulating viruses and immunosuppressive exosomes from the bloodstream. By targeting glycosylated pathogens and exosomes, Aethlon aims to restore immune function and improve patient outcomes in oncology and infectious disease settings.

The Hemopurifier platform leverages proprietary lectin affinity technology to selectively bind and eliminate harmful particles without depleting healthy blood components. Aethlon has advanced the device through human clinical trials, exploring its potential in patients with viral infections—such as hepatitis C and COVID-19—and in oncology patients where tumor‐derived exosomes contribute to immune system evasion. The company continues to refine its technology, pursue regulatory designations, and seek strategic collaborations to expand its clinical development efforts.

Headquartered in San Diego, California, Aethlon Medical was established with a mission to bring innovative extracorporeal therapies to market. Under the leadership of President and Chief Executive Officer Phillip D. Borden, the company engages with regulatory agencies and research institutions across North America and internationally. Aethlon’s research and development operations are complemented by partnerships aimed at accelerating the clinical evaluation of its platform and ultimately delivering new treatment options for patients with urgent medical needs.

Key Stats

• Today's Range: $0.72 to $0.76
• 50-Day Range: $0.65 to $2.19
• 52-Week Range: $0.60 to $8.44
• Volume: 240,531 shs
• Average Volume: 705,153 shs
• Market Capitalization: $1.92 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $56.00
• Consensus Rating: Reduce

Aethlon Medical Stock Analysis - MarketRank™

Aethlon Medical scored higher than 52% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Reduce

Consensus Rating

Aethlon Medical has received a consensus rating of Reduce. The company's average rating score is 1.50, and is based on no buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Aethlon Medical has a consensus price target of $56.00, representing about 7,501.5% upside from its current price of $0.74.

Amount of Analyst Coverage

Aethlon Medical has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Aethlon Medical are expected to grow in the coming year, from ($0.73) to ($0.49) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Aethlon Medical is -0.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Aethlon Medical is -0.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Aethlon Medical has a P/B Ratio of 0.29. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.17% of the float of Aethlon Medical has been sold short.

Short Interest Ratio / Days to Cover

Aethlon Medical has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Aethlon Medical has recently decreased by 93.15%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Aethlon Medical does not currently pay a dividend.

Dividend Growth

Aethlon Medical does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.17% of the float of Aethlon Medical has been sold short.

Short Interest Ratio / Days to Cover

Aethlon Medical has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Aethlon Medical has recently decreased by 93.15%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: 0.32

News Sentiment

Aethlon Medical has a news sentiment score of 0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.77 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Aethlon Medical this week, compared to 1 article on an average week.

Search Interest

18 people have searched for AEMD on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added Aethlon Medical to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Aethlon Medical insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 1.20% of the stock of Aethlon Medical is held by insiders.

Percentage Held by Institutions

Only 1.99% of the stock of Aethlon Medical is held by institutions.

AEMD Stock Analysis - Frequently Asked Questions

How have AEMD shares performed this year?

Aethlon Medical's stock was trading at $6.88 at the beginning of 2025. Since then, AEMD shares have decreased by 89.3% and is now trading at $0.7367.

How were Aethlon Medical's earnings last quarter?

Aethlon Medical, Inc. (NASDAQ:AEMD) posted its earnings results on Wednesday, August, 13th. The medical equipment provider reported ($0.85) EPS for the quarter, missing the consensus estimate of ($0.68) by $0.17.
Read the conference call transcript.

When did Aethlon Medical's stock split?

Aethlon Medical's stock reverse split on Thursday, October 5th 2023.The 1-10 reverse split was announced on Wednesday, October 4th 2023. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, October 4th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

How do I buy shares of Aethlon Medical?

Shares of AEMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Aethlon Medical own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Aethlon Medical investors own include Advanced Micro Devices (AMD), Nokia (NOK), NVIDIA (NVDA), Pfizer (PFE), Plug Power (PLUG), Vaxart (VXRT) and Organigram Global (OGI).

Company Calendar

• Last Earnings: 8/13/2025
• Today: 10/09/2025
• Next Earnings (Estimated): 11/12/2025
• Fiscal Year End: 3/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - HMO
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:AEMD
• CIK: 773910
• Web: www.aethlonmedical.com
• Phone: (858) 459-7800
• Fax: N/A
• Employees: 10
• Year Founded: 1998

Price Target and Rating

• Average Price Target for Aethlon Medical: $56.00
• High Price Target: $56.00
• Low Price Target: $56.00
• Potential Upside/Downside: +7,501.5%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($12.64)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$13.39 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -266.21%
• Return on Assets: -179.46%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.49
• Quick Ratio: 2.49

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.55 per share
• Price / Book: 0.29

Miscellaneous

• Outstanding Shares: 2,599,000
• Free Float: 2,568,000
• Market Cap: $1.91 million
• Optionable: No Data
• Beta: 1.82